Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | November 11, 2015 |
| Target | Astellas Pharma - Global Dermatology |
| Sector | Life Science |
| Buyer(s) | LEO Pharma |
| Sellers(s) | Astellas Pharma |
| Deal Type | Divestiture |
| Deal Value | 675M EUR |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1908 |
| Sector | Life Science |
| Employees | 4,285 |
| Revenue | 1.4B EUR (2022) |
LEO Pharma engages in medical dermatology with a robust R&D pipeline, a wide range of therapies, and a pioneering spirit. LEO Pharma supports people in managing their skin conditions. LEO Pharma was founded in 1908 and is based in Ballerup, Denmark.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science | 1 of 2 |
| Type: Divestiture | 1 of 1 |
| Country: United States | 1 of 2 |
| Year: 2015 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-07-21 |
LEO PDE4 Inhibitor
Ballerup, Denmark LEO PDE4 Inhibitor compound series has the potential for the treatment of psoriasis and other immune-dermatological disorders. |
Sell | $200M |
| Category | Company |
|---|---|
| Founded | 1923 |
| Sector | Life Science |
| Employees | 13,643 |
| Revenue | 1.91T JPY (2025) |
Astellas Pharma is a pharmaceutical company committed to the therapeutic fields of urology, immunology, oncology, neuroscience, and DM complications and metabolic diseases. Astellas Pharma was founded in 1923 and is based in Tokyo, Japan.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 2 |
| Country: United States | 1 of 1 |
| Year: 2015 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-05-16 |
Perseid Therapeutics
Redwood City, California, United States Perseid Therapeutics LLC engages in the discovery, and research and development. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-28 |
Ganymed Pharmaceuticals AG
Mainz, Germany Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. |
Buy | €422M |
